

Brand Name: ITRA Q-200

Composition: Itraconazole capsule BP

Dosage Form: CAPSULE

Category: Antifungal (Systemic Antimycotic)

Packaging Type: BLISTER (MONO PACK)

Packaging: 10 × 1 × 10

Brief Product Introduction:

ITRA Q-200 is a broad-spectrum antifungal capsule developed and manufactured by **AstraEureka Pharmaceutical**, containing Itraconazole 200 mg in pellet form. Itraconazole is a potent triazole antifungal agent used in the treatment of systemic and superficial fungal infections. The pellet formulation ensures sustained release and improved absorption, providing better clinical outcomes in fungal infections of the skin, nails, respiratory tract, and systemic mycoses. ITRA Q-200 acts by inhibiting fungal cytochrome P450 enzymes, thereby blocking ergosterol synthesis, a key component of fungal cell membranes. This leads to fungal cell death and clinical resolution of infection. Indicated in dermatophytosis, candidiasis, aspergillosis, and onychomycosis, it is prescribed under physician supervision.

Composition:

Each hard gelatin capsule contains:

Itraconazole Pellets

equivalent to Itraconazole BP.....200 mg.

Excipients.....q.s.

Key Benefits:

1. Broad-spectrum antifungal activity.
2. Effective in both superficial and systemic mycoses.
3. Sustained-release pellets improve absorption and compliance.
4. Useful in resistant or recurrent fungal infections.
5. Reduces fungal growth and eradicates infection.

Indications:

1. Systemic fungal infections.
2. Dermatophytosis (Tinea infections).
3. Onychomycosis (nail fungal infections).
4. Oropharyngeal and esophageal candidiasis.
5. Aspergillosis (pulmonary fungal infection).
6. Fungal infections unresponsive to topical therapy.

Directions for Use:

1. Swallow whole with water after a full meal.
2. Do not chew or open the capsule.

Dosage and Administration:

1. **Usual Adult Dose:** One capsule (200 mg) once or twice daily depending on severity.
2. Dosage should be adjusted based on indication and physician's discretion.

Safety Information:

1. To be used under medical supervision only.
2. Do not self-medicate or use for viral infections.
3. Regular liver function monitoring is advised during prolonged use.
4. Avoid alcohol during therapy.

Mechanism of Action:

- Itraconazole inhibits the fungal enzyme 14- α demethylase, essential for converting lanosterol to ergosterol, a key component of fungal cell membranes.
- This disruption weakens the membrane integrity, leading to cell leakage and death.
- ITRA Q-200's sustained-release pellets enhance gastrointestinal absorption and maintain steady plasma levels for improved efficacy.

Contraindications:

1. Hypersensitivity to Itraconazole or other azoles
2. Congestive heart failure (in chronic cases)
3. Co-administration with drugs metabolized by CYP3A4 that can prolong QT interval

Side Effects:

1. Nausea, abdominal pain, diarrhea.
2. Headache, dizziness.
3. Elevated liver enzymes.
4. Rare: Hepatotoxicity, hypersensitivity reactions.

Important Notice:

- ITRA Q-200 should only be used when prescribed by a registered medical practitioner.
- Misuse may lead to drug resistance or adverse effects. Regular monitoring is advised in long-term therapy.

Storage Condition:

1. Store below 25°C in a dry place.
2. Protect from moisture and light.
3. Keep out of reach of children.

Packing Information:

- Mono blister pack of **10 × 1 × 10** capsules.

